Parkinson’s, which affect as many 10 million people in the world, is caused by a depletion of
To address this issue, the researchers tested for the first time to
The researchers used mice modeled for Parkinson’s. The animals were separated in three groups. The first one, the control group, did not receive the stem cell implant. The second one, received the implant of stem cells which were not treated with mitomycin C and the third one received the mitomycin C treated cells.
After the injection of 50,000 untreated stem cells, the animals of the second group showed improvement in motor functions but all of them died between 3 and 7 weeks later. These animals also developed intracerebral tumors. In contrast, animals receiving the treated stem cells showed improvement of Parkinson’s symptoms and survived until the end of the observation period of 12 weeks
Furthermore, the scientists have also shown that treating the stem cells with mitomycin C induced a
«This simple strategy of shortly exposing pluripotent stem cells to an
The discovery, reported in the journal Frontiers in Cellular Neuroscience, could pave the way for researchers and physicians to propose a clinical trial using pluripotent stem cells treated with mitomycin C prior to transplant to treat Parkinson’s patients and also other neurodegenerative conditions.
«Our technique with mitomycin C may speed the proposal of clinical trials with pluripotent cells to several human diseases," says Rehen. «It is the first step to make this kind of treatment with stem cells possible.»
Note: Material may have been edited for length and content. For further information, please contact the cited source.
D’Or Institute for Research and Education
Publication
Mariana Acquarone, Thiago Melo, Fernanda G. Meireles Ferreira, Jordano
http://www.neuroscientistnews.com/